These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20080439)

  • 41. Prevalence and genotype characterization of human papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso.
    Djigma FW; Ouédraogo C; Karou DS; Sagna T; Bisseye C; Zeba M; Ouermi D; Gnoula C; Pietra V; Ghilat-Avoid-Belem NW; Sanogo K; Sempore J; Pignatelli S; Ferri AM; Nikiema JB; Simpore J
    Acta Trop; 2011 Mar; 117(3):202-6. PubMed ID: 21167118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Past, present, and future of HPV research: highlights from the 19th International Papillomavirus Conference-HPV2001.
    Villa LL; Bernard HU; Kast M; Hildesheim A; Amestoy G; Franco EL
    Virus Res; 2002 Nov; 89(2):163-73. PubMed ID: 12445656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine.
    Igidbashian S; Boveri S; Bottari F; Vidal Urbinati A; Preti E; Casadio C; Landoni F; Sideri M; Sandri MT
    J Low Genit Tract Dis; 2017 Jan; 21(1):4-8. PubMed ID: 27755229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Yang A; Farmer E; Lin J; Wu TC; Hung CF
    Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modern screening in cervical cancer. Perspectives of HPV prophylactic vaccines.
    Vlădăreanu R; Andrei C
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(1):144-54. PubMed ID: 17595860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus: science and technologies for the elimination of cervical cancer.
    Bosch FX
    Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States?
    Low GM; Attiga YS; Garg G; Schlegal R; Gallicano GI
    Viral Immunol; 2012 Jun; 25(3):174-86. PubMed ID: 22691099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EUROGIN 2008 roadmap on cervical cancer prevention.
    Franceschi S; Cuzick J; Herrero R; Dillner J; Wheeler CM
    Int J Cancer; 2009 Nov; 125(10):2246-55. PubMed ID: 19521965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis.
    Wang H; Qiao YL
    Int J STD AIDS; 2008 Oct; 19(10):680-4. PubMed ID: 18824620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human papilloma virus: diagnostic, treatment and preventive issues.
    Christopoulos P; Deligeoroglou E; Papadias K; Creatsas G
    Akush Ginekol (Sofiia); 2008; 47(1):35-8. PubMed ID: 18642576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HPV vaccination and colposcopy workload of screening programmes.
    Zorzi M; Giorgi-Rossi P
    Vaccine; 2008 Dec; 26(52):6743-4. PubMed ID: 18950669
    [No Abstract]   [Full Text] [Related]  

  • 52. High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.
    Mbatha JN; Taylor M; Kleppa E; Lillebo K; Galappaththi-Arachchige HN; Singh D; Kjetland EF; Baay MFD; Mkhize-Kwitshana ZL
    Infect Dis (Lond); 2017 Aug; 49(8):601-608. PubMed ID: 28403727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of human papillomavirus genotyping.
    Choi YJ; Park JS
    J Gynecol Oncol; 2016 Mar; 27(2):e21. PubMed ID: 26768784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
    Tota JE; Ramanakumar AV; Villa LL; Richardson H; Burchell AN; Coutlée F; Franco EL
    J Infect Dis; 2016 Sep; 214(5):676-84. PubMed ID: 27256157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland.
    Ferguson M; Wilkinson DE; Zhou T
    Vaccine; 2009 Jan; 27(3):337-47. PubMed ID: 19007840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Cape Town declaration on human papillomavirus related disease.
    Williamson AL; Garland S; Palefsky J; Rybicki E; Stanley M; de Sanjosé S
    Papillomavirus Res; 2018 Jun; 5():59-60. PubMed ID: 29294358
    [No Abstract]   [Full Text] [Related]  

  • 59. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.
    Craig BM; Brisson M; Chesson H; Giuliano AR; Jit M
    Clin Ther; 2010 Aug; 32(8):1546-64. PubMed ID: 20728767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of HPV vaccines: from the burden of disease to the health technology assessment approach.
    La Torre G
    Hum Vaccin; 2010 Nov; 6(11):915-7. PubMed ID: 20980798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.